Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company developing immune-based medicines for serious infectious diseases and cancer, and its news flow reflects active clinical and corporate development. Company announcements highlight progress in chronic hepatitis delta (CHD), where Vir Biotechnology is advancing a combination of tobevibart, an investigational broadly neutralizing monoclonal antibody targeting hepatitis B surface antigen, and elebsiran, an investigational hepatitis B virus-targeting siRNA, through the ECLIPSE registrational program.
News updates frequently cover clinical data readouts and milestones, such as Phase 2 SOLSTICE trial results in CHD showing rates of undetectable hepatitis delta virus RNA and safety findings for the tobevibart and elebsiran combination. Additional releases describe enrollment status and timelines for the ECLIPSE 1, 2 and 3 trials, which are designed to provide efficacy and safety data for potential regulatory submissions and to support access and reimbursement in key markets.
Vir Biotechnology also issues news on its oncology portfolio of PRO-XTEN dual-masked T-cell engagers, including VIR-5500 in metastatic castration-resistant prostate cancer, VIR-5818 in HER2-expressing tumors and VIR-5525 in EGFR-expressing solid tumors. These updates may include first-patient-dosed announcements, Phase 1 dose escalation progress, and plans to present safety and efficacy data at scientific meetings.
Corporate and financial communications, such as quarterly results, conference presentations and licensing agreements, also feature prominently. For example, the company has reported on a license agreement with Norgine for CHD commercial rights in Europe, Australia and New Zealand and has provided guidance on its cash runway. Investors and followers of VIR news can use this page to monitor clinical milestones, regulatory-related updates, partnering activity and financial disclosures as the company advances its infectious disease and oncology programs.
Vir Biotechnology (VIR) announced that CEO Marianne De Backer will participate in a fireside chat at the Bank of America Securities 2025 Healthcare Conference. The event is scheduled for Wednesday, May 14 at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada. Investors can access a live webcast of the presentation through the Events & Presentations section of Vir's website, where it will remain archived for 30 days.
Vir Biotechnology has scheduled its first quarter 2025 financial results announcement and corporate update for May 7, 2025. The company will release its Q1 2025 results and corporate updates via press release shortly after market close.
A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET on the same day. Stakeholders can access the call through:
- Webcast: Events & Presentations page on Vir's website
- Phone: U.S. toll-free at +1 (888) 800-8770
- International: +1 (646) 307-1953
- Conference ID: 7568777
The recorded version will be available approximately two hours after the event and will remain accessible for 30 days.
Vir Biotechnology (Nasdaq: VIR) announced upcoming presentations at the European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam, featuring key clinical data from their hepatitis programs. The presentations will include:
1. A 24-week subgroup analysis from the Phase 2 SOLSTICE trial in chronic hepatitis delta, examining the impact of baseline viral parameters and cirrhosis status on treatment responses with tobevibart and elebsiran.
2. 24-week post-treatment follow-up data from the MARCH Phase 2 study, evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa, in chronic hepatitis B patients. Previous end-of-treatment data showed promising rates of hepatitis B surface antigen loss in participants with low baseline HBsAg.
3. In vitro characterization data of elebsiran, an investigational siRNA therapeutic targeting hepatitis B virus.
Brii Biosciences (BRIBY) has provided its full-year 2024 financial results and corporate update, highlighting significant progress in its hepatitis B virus (HBV) functional cure program. The company reported strong cash reserves of US$335.7 million, sufficient to fund operations into 2028.
Key developments include the strategic acquisition of BRII-179's intellectual property for $18 million and advancement of multiple Phase 2b studies. The ENHANCE study completed enrollment in January 2025, while the ENSURE study showed promising 48-week end-of-treatment data, demonstrating higher HBV surface antigen loss rates with elebsiran combination therapy.
Financial results showed a cash position of RMB2,413.4 million, down 9.3% year-over-year. Research and development expenses decreased by 38% to RMB249.8 million, while administrative expenses reduced by 22% to RMB153.2 million. The company reported an increased loss of RMB512.4 million for 2024, up 177.9% from 2023, primarily due to investment-related losses and impairment charges.
Vir Biotechnology (Nasdaq: VIR) has initiated its Phase 3 ECLIPSE registrational program, enrolling the first patient to evaluate the combination of tobevibart and elebsiran for chronic hepatitis delta (CHD) treatment.
The program consists of three trials: ECLIPSE 1 and 2 (Phase 3) for registrational data submission to regulatory agencies, and ECLIPSE 3 (Phase 2b) to support access and reimbursement strategies in European markets. The combination therapy has shown promising results in the SOLSTICE Phase 2 trial, demonstrating ability to reduce hepatitis delta virus to undetectable levels.
CHD, the most severe form of chronic viral hepatitis, typically progresses to cirrhosis and liver failure within 5 years. Currently, there are no approved treatments in the U.S. and options globally. The therapy has received multiple regulatory recognitions, including FDA Breakthrough and Fast Track designations, and EMA Priority Medicines and orphan drug designation.
Vir Biotechnology (VIR) reported its Q4 and full year 2024 financial results, highlighting significant progress in its pipeline programs. The company ended 2024 with $1.10 billion in cash and investments, projecting runway into mid-2027.
Key developments include the upcoming Phase 3 ECLIPSE program for chronic hepatitis delta in H1 2025, with the treatment receiving multiple regulatory designations. Their dual-masked T-cell engagers showed promising results: VIR-5818 demonstrated tumor shrinkage in 50% of participants, while VIR-5500 showed PSA reductions in 100% of prostate cancer patients.
Financial highlights for Q4 2024: Revenue was $12.4 million, R&D expenses were $106.1 million, and net loss was $104.6 million ($0.76 per share). Full-year 2024 showed revenue of $74.2 million and net loss of $522.0 million ($3.83 per share), with a 28% year-over-year reduction in operating expenses.
Vir Biotechnology (Nasdaq: VIR) has announced its executive team's upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company will engage in a fireside chat scheduled for Tuesday, March 4 at 8:50 a.m. PT / 11:50 a.m. ET in Boston, Massachusetts.
The event will be accessible through a live webcast available in the Investors section of Vir Biotechnology's website under Events & Presentations. The recording will remain archived for 30 days following the presentation.
Vir Biotechnology (Nasdaq: VIR) has announced it will provide a corporate update and report its fourth quarter and full year 2024 financial results on February 26, 2025. The announcement will be made after market close, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET.
The financial results and corporate update will be accessible through a press release on the company's website's Investors section. Interested parties can join the conference call via webcast or by phone using the U.S. toll-free number +1 (888) 800-8770 or international number +1 (646) 307-1953, with Conference ID: 7568777. A recording will be available approximately two hours after the event and archived for 30 days.